FDA Updates News 17 October 2025

Ascendis Pharma (ASND) Stock Slides After Q3 Miss and FDA Delay – What Investors Need to Know on December 9, 2025

Ascendis Pharma A/S (NASDAQ: ASND) is back in the spotlight on December 9, 2025, after its share price slipped again while Wall Street continues to project hefty upside and label the name a “Buy” or “Strong Buy.” The Danish biotech,

9 December 2025

Praxis Precision Medicines (PRAX) Stock Surges on FDA Progress and Epilepsy Trial Wins: Latest News and 2026 Forecast

Updated December 5, 2025 – all developments since December 4, 2025 Praxis Precision Medicines, Inc. (NASDAQ: PRAX) has moved back into the market spotlight after a flurry of major announcements on December 4, 2025. The biotech’s stock — already one

5 December 2025

Biotech News · Epilepsy Research · FDA Updates · Investment Forecasts · NASDAQ:PRAX · Stock Market

GSK Stock Outlook December 2025: Q3 Beat, Buybacks and Big FDA Decisions Shape 2026 Forecasts

As of December 3, 2025, GSK plc (LSE:GSK, NYSE:GSK) is trading near multi‑year highs after a year of earnings beats, a revived oncology franchise, heavy share buybacks and an unusually busy FDA calendar for December. At the same time, analysts

3 December 2025

FDA Updates · Investment Strategies · Market Forecasts · NYSE:GSK · Pharma News · Stock Analysis

Pfizer (PFE) Stock on December 2, 2025: Price, Metsera Deal, New FDA Risks and 2026 Outlook

As of late trading on Tuesday, December 2, 2025, Pfizer (NYSE: PFE) shares change hands around $25.10, down roughly 0.7% on the day and sitting in the middle of their 52‑week range of $20.92–$27.69. Yahoo Finance+1 The stock carries a dividend yield

2 December 2025

FDA Updates · Investment Outlook · NYSE:PFE · Pfizer News · Pharma Industry · Stock Analysis

AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength

AbbVie Inc. (NYSE: ABBV) heads into the final month of 2025 with a mixed but generally constructive backdrop for shareholders. The stock is trading in the mid‑$220s per share — around $227 — implying a market capitalization of roughly $400

30 November 2025

Dividends · FDA Updates · Investment Strategies · NYSE:ABBV · Pharma News · Stock Analysis

ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

Key Takeaways ALT stock price today: how Altimmune is trading on November 25, 2025 Altimmune Inc. (NASDAQ: ALT) continues its November rebound. As of early trading on Tuesday, November 25, ALT is changing hands around $5.1 per share, roughly flat

25 November 2025

Biotech News · FDA Updates · Investing · NASDAQ:ALT · Pharmaceutical Industry · Stock Market

PSTV Stock on November 25, 2025: FDA Meeting, Nasdaq Extension and Humana Deal Put Plus Therapeutics Back in Focus

As traders log in on Tuesday, November 25, 2025, Plus Therapeutics (NASDAQ:PSTV) is back on the radar thanks to a cluster of late‑November catalysts: an FDA Type B meeting for lead radiotherapeutic REYOBIQ™, a fresh 180‑day Nasdaq bid‑price extension, and

25 November 2025

Biotech Stocks · FDA Updates · Healthcare Deals · Nasdaq Listings · NASDAQ:PSTV · Stock Market News

Scholar Rock (NASDAQ: SRRK) Soars on FDA Progress, $200M ATM and Q3 2025 Earnings – November 14, 2025 Update

Scholar Rock Holding Corporation (NASDAQ: SRRK) is back in the spotlight as its stock jumps more than 25% on the day after a pivotal FDA meeting, fresh Q3 2025 financial results, and the launch of a new $200 million at-the-market

14 November 2025

Biotechnology · Earnings Reports · FDA Updates · NASDAQ:SRRK · NYSE:NVO · Pharmaceutical Industry · Stock Market

Tenaya Therapeutics (TNYA) on Nov. 8, 2025: FDA Places Clinical Hold on TN‑201 Trial as AHA 2025 Showcases Encouraging MyPEAK‑1 Data

What happened today (Nov. 8) Tenaya Therapeutics (NASDAQ: TNYA) presented new interim results from its MyPEAK‑1 Phase 1b/2a trial evaluating TN‑201, an AAV9 gene‑replacement therapy designed to deliver a working MYBPC3 gene to cardiomyocytes for MYBPC3‑associated hypertrophic cardiomyopathy (HCM). The

8 November 2025

Biotech · Clinical Trials · FDA Updates · Gene Therapy · Medical News · NASDAQ:TNYA

Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears

In summary, Biohaven’s stock is a tale of high stakes in biotech. Recent price swings underscore the uncertainty, but also the potential reward if Biohaven’s bets pay off. With an FDA verdict looming and multiple shots on goal in its

3 November 2025

Biotech News · FDA Updates · Financial Analysis · Investment Strategies · NYSE:BHVN · Stock Market

Salmonella Scare: FDA Upgrades Egg Recall to ‘Highest Risk’ — Are Your Eggs Affected?

Egg supplies and prices remain the backdrop to this story. 163 million U.S. poultry have died from avian flu since 2022, cutting the egg-laying flock by ~11% vs. 2019 reuters.com. Consumers have seen sticker shock – in some cities eggs

22 October 2025

FDA Updates · Food Safety · Health News · NASDAQ:CALM · Product Recalls · Public Health

Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

FEMY Stock Soars on Fertility Buzz Femasys stock has been on a rollercoaster ride in recent sessions. As of October 17, 2025, FEMY traded around the mid-$0.70s per share – more than double its price just a few weeks prior,

17 October 2025

Biotechnology · FDA Updates · Fertility · Medical Innovations · NASDAQ:FEMY · Stock Market

FDA Updates News 17 October 2025 - 9 December 2025